摘要
Background Genetic variations at the interleukin 28B （IL-28B） locus are important in predicting outcome following therapy for chronic hepatitis C virus （HCV） infection. The aim of this research was to evaluate the role of IL-28B single nucleotide polymorphism （SNP） variations in Chinese patients undergoing pegylated interferon-a plus ribavirin （PEG-IFN-a/RBV） treatment. Methods To determine the effect of IL-28B variation on the response to HCV therapy, these variants were genotyped in a cohort of 220 patients who were chronically infected with HCV and received combined PEG-IFN-a/RBV therapy. Results The proportions of rs12979860 CC, CT, and TT genotypes were 71.4%, 25.0%, and 3.6% respectively, in the sustained virological response （SVR） group; 15.8%, 60.5%, and 23.7% respectively, in the null virological response （NVR） group; and 38.1%, 52.4%, and 9.5% respectively, in the relapse （Rel） group （P 〈0.05）. Logistic regression analysis showed that, compared to those having the CC genotype, CT heterozygotes had an increased risk of NVR and Rel （OR=10.95, 95% CI =4.12-29.11, P=1.5×10-7 and OR=3.93, 95% CI =1.86-8.32, P=-2.1×10-4 respectively）. The RNA quantification assay showed that patients with genotype CC exhibited much higher levels of IL-28 expression than those with genotype CT or TT （P 〈0.001）. Conclusions The IL-28B SNP rs12979860 genotype was related to the effectiveness of HCV therapy： patients with the CC rs12979860 genotype had higher rates of SVR than those with the CT or TT genotype, and the CC genotype revealed a significantly higher level of IL-28 mRNA expression.
Background Genetic variations at the interleukin 28B （IL-28B） locus are important in predicting outcome following therapy for chronic hepatitis C virus （HCV） infection. The aim of this research was to evaluate the role of IL-28B single nucleotide polymorphism （SNP） variations in Chinese patients undergoing pegylated interferon-a plus ribavirin （PEG-IFN-a/RBV） treatment. Methods To determine the effect of IL-28B variation on the response to HCV therapy, these variants were genotyped in a cohort of 220 patients who were chronically infected with HCV and received combined PEG-IFN-a/RBV therapy. Results The proportions of rs12979860 CC, CT, and TT genotypes were 71.4%, 25.0%, and 3.6% respectively, in the sustained virological response （SVR） group; 15.8%, 60.5%, and 23.7% respectively, in the null virological response （NVR） group; and 38.1%, 52.4%, and 9.5% respectively, in the relapse （Rel） group （P 〈0.05）. Logistic regression analysis showed that, compared to those having the CC genotype, CT heterozygotes had an increased risk of NVR and Rel （OR=10.95, 95% CI =4.12-29.11, P=1.5×10-7 and OR=3.93, 95% CI =1.86-8.32, P=-2.1×10-4 respectively）. The RNA quantification assay showed that patients with genotype CC exhibited much higher levels of IL-28 expression than those with genotype CT or TT （P 〈0.001）. Conclusions The IL-28B SNP rs12979860 genotype was related to the effectiveness of HCV therapy： patients with the CC rs12979860 genotype had higher rates of SVR than those with the CT or TT genotype, and the CC genotype revealed a significantly higher level of IL-28 mRNA expression.
